指南与共识冠心病外科瓣膜外科心外重症与机械循环支持

STS 2026 心脏术后新发房颤防治临床实践指南

The Society of Thoracic Surgeons 2026 Clinical Practice Guidelines for the Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation After Cardiac Surgery.
指南 / 共识 · Ann Thorac Surg · 2026-04-18

该指南由STS循证外科工作组召集多学科写作组制定,针对心脏手术后新发房颤的预防与治疗提出15条推荐。推荐涵盖8条预防策略、3条术中技术和4条术后治疗,其中2条为Class I推荐,分别涉及围术期口服胺碘酮和血流动力学不稳定POAF的节律转复。指南强调个体化风险评估,并指出高质量证据仍有限。

要点

  • 围术期口服胺碘酮和血流动力学不稳定POAF的节律转复为Class I推荐。
  • 后心包切开术和围术期β受体阻滞剂获Class IIa推荐。
  • 8条Class IIb推荐反映证据不确定领域,3条Class III推荐涉及无获益疗法。

核心结论

  • 2026 STS指南为心脏术后新发POAF的预防和治疗提供最全面的推荐框架。
  • 证据等级因干预而异,心脏术后POAF的高质量数据仍有限。

研究设计与样本

  • 2025年STS多学科写作组采用PICO框架制定临床问题,覆盖术前、术中、术后领域。
  • 按STS标准化方法审查随机对照试验和观察性研究证据,推荐按Class和Level of Evidence分级。

主要发现

  • 共制定15条推荐:8条预防策略、3条术中技术、4条术后治疗。
  • 2条Class I推荐涉及围术期口服胺碘酮和血流动力学不稳定POAF的节律转复。
  • 2条Class IIa推荐支持后心包切开术和围术期β受体阻滞剂。
  • 8条Class IIb推荐反映证据不确定和有限数据领域。
  • 3条Class III推荐涉及无已证实获益的疗法。

关键数值与推荐

  • Class I推荐:围术期口服胺碘酮。
  • Class I推荐:血流动力学不稳定POAF的节律转复。
  • Class IIa推荐:后心包切开术。
  • Class IIa推荐:围术期β受体阻滞剂。
  • Class IIb推荐共8条,Class III推荐共3条。

临床怎么用

  • 围术期可考虑口服胺碘酮预防POAF(Class I)。
  • 血流动力学不稳定POAF应行节律转复(Class I)。
  • 后心包切开术和围术期β受体阻滞剂可合理用于预防(Class IIa)。
  • 应基于个体化风险评估选择治疗,关注药物不良反应。

局限性

  • 心脏术后POAF的高质量数据仍有限。
  • 药理学研究常缺乏剂量和时机的 granularity。
  • 术中操作持续演变,证据等级不一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative atrial fibrillation (POAF) is the most frequent complication after cardiac surgery and is associated with greater morbidity, mortality, length of stay, and cost. Multiple pharmacologic and procedural strategies exist for POAF prevention and treatment, yet practice variation persists. The Society of Thoracic Surgeons (STS) Workforce on Evidence-Based Surgery convened a multidisciplinary writing group to synthesize contemporary evidence and develop guideline recommendations for preventing and treating new-onset POAF after cardiac surgery. METHODS: In 2025, the group used the Population, Intervention, Comparison, Outcome framework to formulate clinical questions spanning preoperative, intraoperative, and postoperative domains. Following standardized STS methodology, evidence from randomized controlled trials and observational studies was reviewed, and recommendations were graded by Class of Recommendation and Level of Evidence. RESULTS: The group developed 15 recommendations: 8 addressing preventive strategies, 3 intraoperative techniques, and 4 postoperative treatments. Two Class I recommendations addressed perioperative oral amiodarone and rhythm cardioversion for hemodynamically unstable POAF. Two Class IIa recommendations supported posterior pericardiotomy and perioperative β-blockers. Eight Class IIb recommendations reflected areas of uncertainty and limited data. Three Class III recommendations addressed therapies without demonstrated benefit. CONCLUSIONS: Levels of Evidence vary across interventions, and high-quality data remain limited for POAF after cardiac surgery. Pharmacologic studies often lack granularity in dose and timing, and intraoperative maneuvers continue to evolve. Individualized risk assessment remains essential given therapy-related adverse effects. The 2026 STS guidelines provide the most comprehensive recommendations focused on POAF after cardiac surgery, offering a framework to standardize care and highlight future investigational priorities.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Chatterjee S, Grant MC, Hui DS, et al. The Society of Thoracic Surgeons 2026 Clinical Practice Guidelines for the Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation After Cardiac Surgery. Ann Thorac Surg. 2026. PMID: 42009116. doi:10.1016/j.athoracsur.2026.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。